ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L04AC18 | BioTech | Risankizumab - 75mg | 10195 | 143719/1 | SKYRIZI | 75mg | 2+2alcohol pads | Injectable solution | SC | Interpharma S.A.L. | Boehringer Ingelheim Pharma GmbH & Co KG | Germany | 4,534,779 L.L | 2.44 | E2 | Abbvie Deutschland GmbH & Co KG | Germany | 2/5/2024 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L04AC18 | BioTech | Risankizumab - 150mg | 11112 | 103421/1 | SKYRIZI | 150mg | 1 | Injectable solution | SC | Interpharma S.A.L. | Abbvie Biotechnology Ltd | USA | 4,534,779 L.L | 2.44 | E2 | Abbvie Deutschland GmbH & Co KG | Germany | 2/5/2024 | |
L04AC18 | BioTech | Risankizumab - 75mg | 10195/945 | 143719/1 | SKYRIZI | 75mg | 2+2alcohol pads | Injectable solution | SC | Interpharma S.A.L. | Boehringer Ingelheim Pharma GmbH & Co KG | Germany | 194,911,251 L.L | 2.44 | E2 | Abbvie Deutschland GmbH & Co KG | Germany | 2/5/2024 | 0 |
L04AC18 | BioTech | Risankizumab - 150mg | 11112/945 | 103421/1 | SKYRIZI | 150mg | 1 | Injectable solution | SC | Interpharma S.A.L. | Abbvie Biotechnology Ltd | USA | 194,911,251 L.L | 2.44 | E2 | Abbvie Deutschland GmbH & Co KG | Germany | 2/5/2024 | 0 |